Association of Leukocyte Subtype Counts With Coronary Atherosclerotic Regression Following Pravastatin Treatment

American Journal of Cardiology

Volumn 104, Issue 4, 2009, Pages 464-469

  Tani, Shigemasa ^a   Nagao, Ken ^a   Anazawa, Takeo ^a   Kawamata, Hirofumi ^a   Furuya, Shingo ^a   Takahashi, Hiroshi ^a   Iida, Kiyoshi ^a   Matsumoto, Michiaki ^a   Washio, Takehiko ^a   Kumabe, Narimichi ^a   Hirayama, Atsushi ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOSORBIDE DINITRATE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BASOPHIL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG SENSITIVITY; EOSINOPHIL; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; JAPANESE; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIVARIATE ANALYSIS; NEUTROPHIL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; VOLUMETRY;

AGED; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; PRAVASTATIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 67849106939     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.04.009     Document Type: Article

References (23)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
2. Freidman G.D., Klatsky A.L., and Siegelaub A.B. The leukocyte count as a predictor of myocardial infarction. N Engl J Med 290 (1974) 1275-1278
3. Madjid M., Awan I., Willerson J.T., and Casscells S.W. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 44 (2004) 1945-1956
4. Salonen R., and Salonen J.T. Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis 81 (1990) 33-40
5. Gerrity R.G. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 103 (1981) 181-190
6. Gerrity R.G. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am J Pathol 103 (1981) 191-200
7. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., and Fallon J.T. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90 (1994) 775-778
8. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith Jr. S.C., Taubert K., Tracy R.P., Vinicor F., and Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
9. Teramoto T., Sasaki J., Ueshima H., Egusa G., Kinoshita M., Shimamoto K., Daida H., Biro S., Hirobe K., Funahashi T., Yokote K., and Yokode M. Treatment-therapeutic lifestyle modification. J Atheroscler Thromb 15 (2008) 109-115
10. Ishikawa K., Tani S., Watanabe I., Matsumoto M., Furukawa K., Nomoto K., Nomoto K., Kushiro T., Nagao K., and Kanmatsuse K. Effect of pravastatin on coronary plaque volume. Am J Cardiol 92 (2003) 975-977
11. Tani S., Watanabe I., Anazawa T., Kawamata H., Tachibana E., Furukawa K., Sato Y., Nagao K., Kanmatsuse K., Kushiro T., and Surugadai Atherosclerosis Regression Investigators. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol 96 (2005) 1089-1094
12. Lee A.J., Mowbray P.I., Lowe G.D., Rumley A., Fowkes F.G., and Allan P.L. Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation 97 (1998) 1467-1473
13. Elkind M.S., Cheng J., Boden-Albala B., Paik M.C., and Sacco R.L. Elevated white blood cell count and carotid plaque thickness: the northern Manhattan stroke study. Stroke 32 (2001) 842-849
14. van der Meer I.M., de Maat M.P.M., Bots M.L., Breteler M.M.B., Meijer J., Kiliaan A.J., Hofman A., and Witteman J.C.M. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 22 (2002) 838-842
15. Hunt K.J., Pankow J.S., Offenbacher S., Kritchevsky S.B., Duncan B.B., Shahar E., Sharrett A.R., and Heiss G. B-mode ultrasound-detected carotid artery lesions with and without acoustic shadowing and their association with markers of inflammation and endothelial activation: the atherosclerosis risk in communities study. Atherosclerosis 162 (2002) 145-155
16. Chapman C.M., Beilby J.P., McQuillan B.M., Thompson P.L., and Hung J. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke 35 (2004) 1619-1624
17. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., Ganz P., and Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
18. Bickel C., Rupprecht H.J., Blankenberg S., Espiniola-Klein C., Schlitt A., Rippin G., Hafner G., Treude R., Othman H., Hofmann K.P., Meyer J., and AtheroGene Investigators. Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 89 (2002) 901-908
19. Shah P.K., Kaul S., Nilsson J., and Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming. part I. Circulation 104 (2001) 2376-2383
20. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J.C., Schoenhagen P., Crowe T., Cain V., Wolski K., Goormastic M., Tuzcu E.M., and ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
21. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., Nakaya N., Nishimoto S., Muranaka M., Yamamoto A., Mizuno K., Ohashi Y., and MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 (2006) 1155-1163
22. Takayama T., Hiro T., Yamagishi M., Daida H., Saito S., Yamaguchi T., and Matsuzaki M. Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects). Circ J 71 (2007) 271-275
23. Miyauchi K., Kimura T., Morimoto T., Nakagawa Y., Yamagishi M., Ozaki Y., Hiro T., Daida H., and Matsuzaki M. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. Circ J 70 (2006) 1624-1628